SAR342434

DRUG4 trials

Sponsors

Sanofi

Conditions

Type 1 DiabetesType 1 Diabetes MellitusType 2 Diabetes Mellitus

Phase 1

A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes

CompletedNCT02273258

SanofiType 1 Diabetes

Start: 2013-03-31End: 2013-07-31Updated: 2014-10-23

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

CompletedNCT02603510

SanofiType 1 Diabetes Mellitus

Start: 2015-11-30End: 2016-04-30Updated: 2016-05-19

Phase 3

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

CompletedNCT02273180

SanofiType 1 Diabetes Mellitus

Start: 2014-10-31End: 2016-07-31Updated: 2018-01-18

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

CompletedNCT02294474

SanofiType 2 Diabetes Mellitus

Start: 2015-01-31End: 2016-02-29Updated: 2018-01-18

Related Papers

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.

2018-01-2314 citations

Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.

2017-12-1219 citations

Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.

2017-08-3026 citations

Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.

2017-02-0922 citations